RCUS
Arcus Biosciences·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RCUS
Arcus Biosciences, Inc.
A clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer
Biological Technology
04/30/2015
03/15/2018
New York Stock Exchange
627
12-31
Common stock
3928 Point Eden Way, Hayward, CA 94545
--
Arcus Biosciences, Inc., was incorporated in Delaware on April 30, 2015. They are a clinical-stage biopharmaceutical company dedicated to creating innovative cancer immunotherapies by exploiting underdeveloped biological opportunities. Specifically, they target well-characterized biological pathways and provide important scientific data to support their importance in regulating the immune response to cancer, both in molecules under development and in the presence of molecules with suboptimal distribution. To take advantage of these pathways, they have built strong and efficient discovery capabilities to create and optimize highly differentiated small molecule immuno-oncology product candidates. Since their inception in 2015, they have built a broad portfolio of small molecule and antibody product candidates, and they plan to jointly develop internal combination products. They have initiated clinical trials of two state-of-the-art product candidates that are expected to generate data in 2018, and they expect to have clinical data from their first product portfolio in the first half of 2019. They plan to launch two add-on product candidates to enter clinical trials by the end of 2018. Members of the Arcus team have worked together for more than 10 years to discover innovative small molecule product candidates at companies such as Tularik Inc., Amgen, Inc., and Flexus Biosciences, Inc.
Company Financials
EPS
RCUS has released its 2025 Q3 earnings. EPS was reported at -1.27, versus the expected -1.29, beating expectations. The chart below visualizes how RCUS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RCUS has released its 2025 Q3 earnings report, with revenue of 26.00M, reflecting a YoY change of -45.83%, and net profit of -135.00M, showing a YoY change of -46.74%. The Sankey diagram below clearly presents RCUS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
